ASH 2020 | CRB-401: ide-cel for R/R multiple myeloma
Idecabtagene Vicleucel (ide-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets the B-cell maturation antigen (BCMA). In this Video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the Phase I CRB-401 (NCT02658929) study, a non-randomized, open-label, multi-site study of idecabtagene vicleucel in adults with relapsed/refractory (R/R) multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultant: Kite/Gilead, Celgene/BMS, JUNO/BMS, BlueBird Bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Iovance, Takeda, Fosun Kite
Grant/Research Support: Kite/Gilead, Celgene, BlueBird Bio, Janssen, Legend Biotech, Merck, Takeda, Boston Scientific
Data safety monitoring board: Sorrento
All funds paid to Mayo Clinic, no personal compensation.
